Hua Jinghan, Wang Zhe, Cheng Xiaoxun, Dai Jiaojiao, Zhao Ping
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, Zhejiang, China.
Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230000, Anhui, China.
Cancer Drug Resist. 2025 Mar 28;8:17. doi: 10.20517/cdr.2024.195. eCollection 2025.
Acquired drug resistance is a main factor contributing to cancer therapy failure and high cancer mortality, highlighting the necessity to develop novel intervention targets. Circular RNAs (circRNAs), an abundant class of RNA molecules with a closed loop structure, possess characteristics including high stability, which provide unique advantages in clinical application. Growing evidence indicates that aberrantly expressed circRNAs are associated with resistance against various cancer treatments, including targeted therapy, chemotherapy, radiotherapy, and immunotherapy. Therefore, targeting these aberrant circRNAs may offer a strategy to improve the efficiency of cancer therapy. Herein, we present a summary of the most recently studied circRNAs and their regulatory roles on cancer drug resistance. With the advances in artificial intelligence (AI)-based bioinformatics algorithms, circRNAs could emerge as promising biomarkers and intervention targets in cancer therapy.
获得性耐药是导致癌症治疗失败和癌症高死亡率的主要因素，这凸显了开发新型干预靶点的必要性。环状RNA（circRNAs）是一类丰富的具有闭环结构的RNA分子，具有高稳定性等特点，这在临床应用中具有独特优势。越来越多的证据表明，异常表达的circRNAs与对各种癌症治疗的耐药性有关，包括靶向治疗、化疗、放疗和免疫治疗。因此，针对这些异常circRNAs可能提供一种提高癌症治疗效率的策略。在此，我们总结了最近研究的circRNAs及其对癌症耐药性的调控作用。随着基于人工智能（AI）的生物信息学算法的进展，circRNAs可能成为癌症治疗中有前景的生物标志物和干预靶点。
